Risk factors for strongyloidiasis hyperinfection and clinical outcomes

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 37, Issue 5, 2006, Pages 875-884

  Asdamongkol, Nakhon ^a   Pornsuriyasak, Prapaporn ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751581211     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Adedayo O, Grell G, Ballot P. Hyperinfective strongyloidiasis in the medical ward: review of 27 cases in 5 years. South Med J 2002; 95: 711-6.
2. Berk SL, Verghese A, Alvarez S, Hall K, Smith B. Clinical and epidemiologic features of strongyloidiasis. A prospective study in rural Tennessee. Arch Intern Med 1987; 147: 1257-61.
3. Brandt de Oliveira R, Voltarelli JC, Meneghelli UG. Severe strongyloidiasis associated with hypogammaglobulinaemia. Parasite Immunol 1981; 3: 165-9.
4. Carvalho EM, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26: 487-97.
5. Davidson RA, Fletcher RH, Chapman LE. Risk factors for strongyloidiasis. A case-control study. Arch Intern Med 1984; 144; 321-4.
6. de Messias IT, Telles FQ, Boaretti AC, Sliva S, Guimarres LM, Genta RM. Clinical, immunological and epidemiological aspects of strongyloidiasis in an endemic area of Brazil. Allergol Immunopathol (Madr) 1987; 15: 37-41.
7. Fardet L, Genereau T, Poirot JL, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: Case series and literature review. J Infect 2006 (in press).
8. Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis 1989; 11: 755-67.
9. Genta RM. Dysregulation of strongyloidiasis: a new hypothesis. Clin Microbiol Rev 1992; 5: 345-55.
10. Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982; 76: 114-8.
11. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sanchez-Sanchez P, Matogo-Oya J, Rodriguez-Calabuig D. Efficacy and safety of Ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5: 2615-9.
12. Ishida T, Appassakij H, Takao S, Settheetham-Ishida W, Tiwawech D, Duangchan P. Human T-lymphotropic retrovirus type-1 in Thailand. Southeast Asian J Trop Med Public Health 2000; 31 (suppl 1): 143-5.
13. Jongsuksuntigul P, Intapan PM, Wongsaroj T, et al. Prevalence of Strongyloides stercoralis infection in northeastern Thailand (agar plate culture detection). J Med Assoc Thai 2003; 86: 737-41.
14. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromized population. Clin Microbiol Rev 2004; 17: 208-17.
15. Lam CS, Tong MK, Chan KM, Siu YR Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25: 14-8.
16. Leelarasamee A, Nimmannit S, Na Nakorn S, Aswapokee N, Aswapokee P, Benjasuratwong Y, Disseminated strongyloidiasis: report of seven cases. Southeast Asian J Trop Med Public Health 1978; 9: 539-42.
17. Naquira C, Jimenez G, Guerra JG, Bernal R, Nalin DR, Neu D, Aziz M. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989; 40: 304-9.
18. Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis 1995; 21: 675-7.
19. Pitisuttithum P, Supanaranond W, Chindanond D. A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis. Southeast Asian J Trop Med Public Health 1995; 26: 735-8.
20. Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 2004; 35: 531-4.
21. Roman-Sanchez P, Pastor-Guzman A, Moreno-Guillen S, et al. High prevalence of Strongyloides stercoralis among farm workers on the Mediterranean coast of Spain: analysis of the predictive factors of infection in developed countries. Am J Trop Med Hyg 2003; 69: 336-40.
22. Scowden EB, Schaffner W, Stone WJ, Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57: 527-44.
23. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33: 1040-7.
24. Sithithaworn P, Srisawangwong T, Tesana S, et al. Epidemiology of Strongyloides stercoralis in north-east Thailand: application of the agar plate culture technique compared with the enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg 2003; 97: 398-402.
25. Toma H, Sato Y, Shiroma Y, Kobayashi J, Shimabukuro I, Takara M. Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa, Japan. Southeast Asian J Trop Med Public Health 2000; 31; 147-51.
26. Urwijitaroon Y, Barusrux S, Puapairoj C, Romphruk A, Khampeera P. Seroepidemiology of HTLV-I infection in northeast Thailand: a four year surveillance. J Med Assoc Thai 1997; 80 (suppl 1): S102-5.